59907-23-2

Basic information

• Product Name: Methyl 5-tert-butylfuran-2-carboxylate
• Synonyms: Methyl 5-tert-butylfuran-2-carboxylate;NSC 69079
• CAS NO: 59907-23-2
• Molecular Formula: C10H14O3
• Molecular Weight: 182.21636
• Mol File: 59907-23-2.mol

Chemical Properties

• Boiling Point: 243.8°Cat760mmHg
• Flash Point: 101.3°C
• Appearance: /
• Density: 1.03g/cm³
• Vapor Pressure: 0.0314mmHg at 25°C
• Refractive Index: 1.463
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Methyl 5-tert-butylfuran-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 5-tert-butylfuran-2-carboxylate(59907-23-2)
• EPA Substance Registry System: Methyl 5-tert-butylfuran-2-carboxylate(59907-23-2)

Safety Data

• Hazardous Substances Data: 59907-23-2(Hazardous Substances Data)

Usage

Uses

Used in Flavor and Fragrance Industry:
Methyl 5-tert-butylfuran-2-carboxylate is used as a flavoring agent for its sweet, fruity, and caramel-like odor, adding depth and complexity to various fragrances and scents.
Used in Pharmaceutical Production:
Methyl 5-tert-butylfuran-2-carboxylate is utilized in the production of pharmaceuticals, where its unique properties contribute to the development of new medicinal compounds.
Used in Food Industry:
In the food industry, Methyl 5-tert-butylfuran-2-carboxylate is used as a flavoring agent to impart a sweet, fruity, and caramel-like taste to food products, enhancing their overall flavor profile.
Safety:
Methyl 5-tert-butylfuran-2-carboxylate is considered a safe chemical when used in accordance with proper handling and storage protocols, ensuring minimal risk to human health and the environment.

InChI:InChI=1/C10H14O3/c1-10(2,3)8-6-5-7(13-8)9(11)12-4/h5-6H,1-4H3

Upstream product

• 611-13-2 2-furoic acid methyl ester 
• 507-20-0 tertiary butyl chloride 
• 507-19-7 t-butyl bromide 
• 109-69-3 n-Butyl chloride 
• 78-77-3 Isobutyl bromide 
• 7446-70-0 aluminium trichloride 
• 78-76-2 s-butyl bromide 
• 630-19-3 pivalaldehyde 
• 558-17-8 tert-Butyl iodide 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 56311-39-8 5-tert-butylfuran-2-carboxylic acid 
• 216574-57-1 methyl 3-amino-5-tert-butylfuran-2-carboxylate 

Downstream Products

• 1334684-76-2 5-tert-butyl-N-[4-methyl-3-[4-(5-morpholin-4-ylpyridin-3-yl)triazol-1-yl]phenyl]-4-[(propan-2-ylamino)methyl]furan-2-carboxamide 
• 216574-57-1 methyl 3-amino-5-tert-butylfuran-2-carboxylate 
• 634171-67-8 4-chloromethyl-5-tert-butylfuran-2-carboxamide 
• 701216-63-9 4-chloromethyl-5-tert-butylfuran-2-carboxylic acid chloride 

Relevant articles and documents

Regioselective Pd-catalyzed α-alkylation of furans using alkyl iodides

Herein, direct alkylation of the C-H bond at the α-position of furans catalyzed by palladium catalyst is reported. This protocol targets α-alkylfurans, achieving moderate to good yields under very practical reaction conditions. With a broad scope of substrates and good functional group tolerance, this method will has promising utility in medicinal chemistry.

Iron-Catalyzed Oxidative Decarbonylative α-Alkylation of Acyl-Substituted Furans with Aliphatic Aldehydes as the Alkylating Agents

A protocol for FeCl2-catalyzed oxidative decarbonylative α-alkylation of acyl furans using alkyl aldehydes as the alkylating agents has been developed. This protocol affords α-alkyl-α-acylfurans in moderate to good yields in a practical and sustainable fa

PYRIDYLTRIAZOLES

The present invention encompasses compounds of general formula (1) wherein the groups R0 to R3 and L are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

B-RAF KINASE INHIBITORS

The present invention encompasses compounds of general formula (1) where in the groups R0to R3 and L are defined as in claim 1, which are suitable for the 5 treatment of diseases characterised by excessive or abnormal cell proliferat

RAF KINASE INHIBITORS

Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

Inhibition of p38 kinase activity by aryl ureas

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.